Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinically Significant Prostate Cancer in Patients Undergoing Holmium Laser Enucleation of Prostate for Benign Hyperplasia: A Preoperative Nomogram and a Postoperative Surveillance Protocol.

Journal of endourology·2026
Same author

Development and validation of a machine learning model for predicting 30-day major morbidity and mortality following radical cystectomy: An American College of Surgeons National Surgical Quality Improvement Program study.

BJUI compass·2026
Same author

Insights from developing an infection prevention internship for Master of Public Health students across 2 healthcare systems.

American journal of infection control·2026
Same author

Multiparametric MRI in prostate cancer active surveillance: results from the Miami Active Surveillance Trial (MAST) trial.

BJU international·2026
Same author

Evaluating MRI findings and biopsy strategies to maximize detection of grade progression in men on active surveillance for prostate cancer.

Urologic oncology·2026
Same author

mpMRI-Based Risk Estimation to Optimize Prostate Cancer Patient Selection for Active Surveillance.

Cancers·2026

Related Experiment Video

Updated: Jun 17, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Biomarkers for prostate cancer detection.

Amanda Beth Reed1, Dipen J Parekh

  • 1Department of Urology, University of Texas Health Sciences Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78284-7840, USA. reeda2@uthscsa.edu

Expert Review of Anticancer Therapy
|December 18, 2009
PubMed
Summary

New prostate cancer biomarkers are needed because prostate-specific antigen (PSA) lacks specificity. This review covers advancements in novel biomarkers for prostate cancer detection and prognosis.

More Related Videos

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization
07:34

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Published on: November 17, 2023

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
08:05

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Published on: June 10, 2025

Related Experiment Videos

Last Updated: Jun 17, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization
07:34

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Published on: November 17, 2023

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
08:05

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Published on: June 10, 2025

Area of Science:

  • Urology
  • Oncology
  • Biomarker Discovery

Background:

  • Prostate-specific antigen (PSA) has been a standard for prostate cancer monitoring since 1986 and for screening since 1994.
  • Limited specificity of PSA necessitates the development of new biomarkers for accurate prostate cancer detection.
  • Current biomarkers are insufficient for determining the need for treatment in all prostate cancer cases.

Purpose of the Study:

  • To review the development of novel biomarkers for prostate cancer detection.
  • To discuss advancements in biomarkers for prostate cancer disease prognostication.
  • To highlight recent progress and topical issues in biomarker development and validation.

Main Methods:

  • Literature review focusing on recent advancements in prostate cancer biomarker research.
  • Analysis of topical issues concerning the development and validation of new diagnostic and prognostic markers.
  • Synthesis of information on novel biomarkers beyond prostate-specific antigen (PSA).

Main Results:

  • Significant progress has been made in identifying and validating novel biomarkers for prostate cancer.
  • Emerging biomarkers show promise for improved specificity in cancer detection compared to PSA.
  • New markers are being developed to aid in disease prognostication and treatment decisions.

Conclusions:

  • Novel biomarkers are crucial for overcoming the limitations of PSA in prostate cancer management.
  • Continued research and validation are essential for integrating new biomarkers into clinical practice.
  • Advancements in biomarker technology offer improved prospects for accurate prostate cancer diagnosis and personalized treatment.